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Abstract
Abnormal protein aggregation has been implicated in neurodegenerative processes in human neurological
disorders, such as Alzheimer’s disease and Parkinson’s disease. Recently, studies have established a novel concept
that protein aggregates are transmitted among neuronal cells. By extension, such interneuronal aggregate
transmission has been hypothesized to be the underlying mechanism for the pathological and clinical disease
progression. However, the precise mechanism of the interneuronal aggregate transmission remains ill-defined.
Recent reports have suggested that exosomes, a specific group of extracellular vesicles that are involved in
intercellular transfer of cellular macromolecules such as proteins and RNAs, could play an important role in the
aggregate transmission among neurons. Here, we review various types of extracellular vesicles and critically
evaluate the evidence supporting the role of exosomes in interneuronal aggregate transmission and
neurodegeneration. We also discuss the competing mechanisms other than the exosome-mediated transmission.
By doing so, we aim to assess the current state of knowledge on the mechanism of interneuronal aggregate
transmission and suggest the future directions of research towards understanding the mechanism.
Keywords: Neurodegenerative diseases, Disease progression, Cell-to-cell transmission, Protein aggregation,
Neurodegeneration
Introduction
Aggregation of specific proteins is the common patho-
logical feature of neurodegenerative diseases, such as
Alzheimer’s disease (AD) Parkinson’s disease (PD), and
amyotrophic lateral sclerosis (ALS) [7, 22]. These protein
aggregates compose different types of inclusions. In AD,
amyloid β (Aβ) peptides and hyperphosphorylated tau
are deposited in senile plaques and neurofibrillary tan-
gles (NFTs), respectively [7, 22]. PD is characterized by
α-synuclein aggregates in the forms of Lewy bodies and
Lewy neurites [7, 22, 34]. Inclusion bodies containing ag-
gregates of TAR DNA-binding protein 43 (TDP-43) exist
in ALS patients [7, 22].
In general, neuropathological protein aggregates tend
to develop at a few discrete loci in the brain and spread
to other brain areas as the diseases progress. Each type
of pathological aggregates exhibits its own stereotypical
pattern of spreading [7, 8, 17, 22]. For example, tau in-
clusions in AD are first observed in the transentorhinal
cortex and spread through the hippocampus to the neo-
cortex areas [5]. On the other hand, Lewy bodies and
Lewy neurites in PD may follow an ascending pattern
from the lower brainstem and olfactory bulb through
the midbrain and limbic system, and finally to the neo-
cortex [6], though there have been multiple examples of
cases that do not follow this pattern of progression [21].
However, whether the spreading of pathological protein
aggregates itself causes neurodegeneration and disease
progressions is uncertain. Nevertheless, significant corre-
lations exist between the regional progression of aggre-
gate pathology and the sequential development of
clinical symptoms in these diseases. Therefore, we might
be able to solve the mechanism of clinical disease pro-
gression by understanding the machinery underlying the
aggregate spreading.
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Recently, a large body of evidence has supported the
involvement of cell-to-cell transmission in the aggregate
spreading. Specifically, exosomes have been the subject
of discussion as the vehicle for the cell-to-cell transmis-
sion. In this review, we will define the exosome in rela-
tion to other extracellular vesicles. Next, we will provide
evidence for the roles of exosomes in aggregate spread-
ing and limitations of the existing studies. Finally, we
will discuss what lies ahead in comprehending the mech-
anism of the intercellular aggregate transmission.
Cell-to-cell transmission of aggregated proteins
Aggregation process is a nucleation-dependent process,
which requires a nucleus formation during the lag phase
[22]. When pre-formed aggregates are present, the ag-
gregation process bypasses the lag phase and rapidly
produces aggregates using the pre-formed aggregates as
seeds (Fig. 1). This has been the molecular principle
underlying the prion infectivity and transmissibility. The
same principle can be applied to interneuronal transmis-
sion of the aggregated proteins other than prion. The
seeding-dependent mechanism has not been completely
proven; there are other possibilities by which the protein
aggregates are propagated through the interneuronal ag-
gregate transfer [27, 28]. Although the precise mechan-
ism of the transmission remains ill-defined, there are
ample experimental supports for interneuronal aggregate
transmission in both cells and animals. However, in
order for the cytoplasmic protein aggregates to propa-
gate among the neuronal cells, they have a significant
challenge: the aggregates have to be secreted from one
neuron and transferred to another.
Such problem of this barrier has begun to be ad-
dressed as some experiments showed that tau, α-
synuclein, and other aggregated proteins were secreted
from neurons [7]. α-synuclein and tau have been shown
to be secreted through an endoplasmic reticulum/Golgi-
independent pathway, which are collectively referred to as
unconventional secretory pathway [2, 14, 24–26, 34, 43].
Physiological functions of the secreted protein aggregates
are unknown. The extracellular aggregates may regulate
synaptic activity [9] and inflammatory responses [23].
However, the dichotomy between physiological and
pathological functions of these extracellular aggregates
Fig. 1 Kinetic principle of protein aggregation underlies the intercellular aggregate transmission. a Simplified scheme illustrating the kinetics of
protein fibrillation and seeded polymerization. Addition of pre-formed fibrils drastically reduced the lag phase. b Illustration of seeded
polymerization principle in cell-to-cell aggregate transmission. When protein aggregates are transferred from one cell to another, the transferred
aggregates could act as ‘seeds’ in the recipient cells
Lim and Lee Acta Neuropathologica Communications  (2017) 5:64 Page 2 of 8
remains fuzzy. Among the unconventional secretory
pathways, the exosome-associated exocytosis has
attracted much attention because this particular
mechanism has been shown to be involved in the se-
cretion of many disease-linked proteins, including
prion, Aβ, α-synuclein and tau (see below), as well as
in both physiological and pathogenic processes in hu-
man health and disease.
Extracellular vesicles and exosomes
Cells secrete a variety of membranous vesicles during
their lives. There are many types of extracellular vesicles:
apoptotic bodies, microvesicles/membrane particles,
exosomes, etc. (Fig. 2). Each type of these vesicles has its
own size, marker proteins, and different secretion path-
way. Microvesicles are large (>100 nm diameter) mem-
branous vesicles produced by shedding/budding/
blebbing from the plasma membrane of various cell
types [19, 31, 36, 38, 39]. These vesicles have irregular
shapes and their biomarkers, such as integrins, selectins,
and CD40 [31]. Membrane particles are also originated
from the plasma membrane and are round-shaped vesi-
cles in 50-80 nm diameter. CD133 (prominin-1) is their
biomarker, not CD63 [30]. On the other hand, exosomes
are intraluminal vesicles (ILVs) within the multivesicular
bodies (MVBs) secreted when MVBs are fused with the
plasma membrane. They are 50-100 nm in diameter
identified by methods such as electron microscopy (EM)
and nanoparticle tracing analysis (NTA). Although there
are descriptions on exosomes and other extracellular
vesicles, currently there is no consensus criteria to define
different types of EVs [32, 47]. Extracellular vesicles (par-
ticularly microvesicles and exosomes) often overlap in
size and share some surface markers (e.g., tetraspanins
CD9, CD63, CD81, etc.) [19, 29, 31, 36, 38, 39]. The
cup-shaped morphology of exosomes is known to be an
artifact of TEM fixation [41]. More studies with im-
proved procedure for exosome preparation would be ne-
cessary for identification of specific markers for
exosomes.
Exosomes are purified by the specific procedure, which
involve differential ultracentrifugation with cell culture
supernatant followed by a rate-zonal centrifugation
(Table 1) [41]. Exosomes are located at the 1.10–1.20 g/
mL density fraction [19, 31, 38, 39]. Although this pro-
cedure has been widely used, some contamination of
serum components could not be avoided [32]. There are
alternative procedures available, including size exclusion,
immunoaffinity isolation, and polymeric precipita-
tion [45]. However, the benefits of these procedures over
the conventional centrifugation procedure has not been
established yet. Exosomes and other extracellular vesi-
cles may function as vehicles for transportation of mac-
romolecules from one cell to another. Exosomes contain
not only proteins but also RNAs and DNAs. Transfer of
these macromolecules may play roles in several bio-
logical processes, such as innate and acquired immunity
and angiogenesis, as well as in human diseases, such as
Fig. 2 Extracellular vesicles. Only exosomes, microvesicles and membrane particles are shown here for simplification, however, more vesicle types
may be present in the extracellular space. Exosomes are generated by exocytosis of MVBs, and microvesicles are formed by budding/blebbing of
the plasma membrane. Membrane particles also formed by the similar mechanism as microvesicles, but the biological markers are different
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neurodegenerative diseases and carcinogenesis and me-
tastasis [47].
Literature arguing the role of exosomes in aggregate
transmission
Recent studies suggest that exosomes play important
roles in interneuronal transmission of pathogenic pro-
teins and neurodegeneration. The first example was pro-
vided in a prion model. Both cellular prion (PrPc) and
scrapie form of prion (PrPsc) proteins were released into
the extracellular space in association with exosomes
[16]. The exosome-associated PrPsc was infectious [16].
Later, it was shown that some Aβ peptides generated
from the β- and γ-cleavage of amyloid precursor protein
(APP) in endosomes were routed to MVBs and secreted
by the exosomal pathway [35]. Furthermore, exosomal
proteins were found in the amyloid plaques of AD pa-
tient brains [35]. Injection of the exosome preparations
into 5xFAD mouse brains promoted aggregation of
Aβ1–42 [13]. Inhibition of exosome-associated exocyt-
osis by intraperitoneal injections of GW4869, an inhibi-
tor of neutral sphingomyelinase-2 (nSMase2; a ceramide
synthesis regulator which is essential for subtype of exo-
some biogenesis in MVBs) reduced the Aβ1–42 plaque
load in vivo [13]. These suggest that exosomes have their
role in AD pathology, triggering aggregation and depos-
ition of amyloid plaques.
Tau was also shown to be secreted via the exosomal
pathway [37, 44]. Exosomal tau secretion was identified
in primary neurons and tau overexpressing N2a cell cul-
ture media. Exosome-associated phospho-tau (AT270-
positive) was present in human CSF [37]. The exosomes
with associated tau proteins were taken up by neurons
and microglia, and induced tau inclusions [44]. Exo-
somes from CSF samples were also able to promote tau
aggregation in cultured N2a cells [44]. Microglia also se-
crete tau via exosomes and tau propagation is reduced
significantly by inhibition of exosome synthesis [4].
When microglial nSMase2 was silenced by siRNA or
pharmacologically inhibited with GW4869, exosome-
associated secretion of tau and propagation of tau path-
ology were reduced [4].
In Parkinson’s model, α-synuclein was also secreted
via the exosomal pathway in a calcium-dependent man-
ner [15]. These exosomes can be transferred to recipient
cells via endocytosis [12], and the transfer was increased
when lysosomes were impaired [3]. Additionally,
exosome-associated α-synuclein oligomers were taken
up by recipient cells more efficiently and had higher
toxicity than free α-synuclein oligomers [10]. Exo-
somes isolated from the CSF of PD and DLB patients
were shown to contain pathogenic species of α-synu-
clein and were able to induce oligomerization of sol-
uble α-synuclein [40]. Injection of exosomes isolated
from DLB patients into the brain led to spreading of
a-synuclein aggregates [33].
Recently, another way that exosomes contribute to the
disease propagation was suggested. Exosomes can accel-
erate in vitro oligomerization of recombinant α-
synuclein monomer and increase toxicity of these pro-
teins [18]. This study also showed that the accelerated
oligomerization was partly due to the lipid contents;
gangliosides of the exosomal membranes. Similarly, Aβ
assembly is markedly accelerated by incubation with the
exosome fraction from the PC12 cell culture media [48].
Critiques to the exosome theory in aggregate transmission
Although there is a body of literature supporting the role
of exosomes in the interneuronal aggregate propagation,
there are some issues that need clarification. First, not
all studies prepared exosomes in a proper way. As men-
tioned above, a pure exosome preparation requires both
differential ultracentrifugation and rate-zonal centrifuga-
tion. Differential ultracentrifugation alone results in mix-
ture of many different types of extracellular vesicles.
Even after rate-zonal centrifugation, the exosome prep-
aration still may contain contaminated non-exosomal
vesicles, which necessitates electron microscopy analysis
with immune-gold labeling [41]. As summarized in
Table 2, in some studies, exosome preparations were ob-
tained from the differential ultracentrifugation without
the rate-zonal centrifugation with sucrose gradient being
performed. These preparations would contain not only
exosomes, but also other extracellular vesicles such as
microvesicles and membrane particles.
Another issue is that pathogenic proteins in association
with exosomes represent only a minor part of the total se-
creted pathogenic proteins [14, 35]. Only a little fraction
(<1%) of total secreted Aβ into the extracellular space is
shown to be exosome-associated [35]. In case of α-
synuclein, less than 3% of the total secreted protein seems
to be associated with exosome [14]. However, low represen-
tation in quantity does not necessarily indicate insignificant
functional roles. Danzer et al. [10] showed that exosome-
Table 1 Procedure of exosome preparation [41]
1. Differential ultracentrifugation
Culture supernatant or fluid – at each of steps, the supernatant is used
for following step.
⇒ 300 x g, 10 min (→ Pellet: cells)
⇒ 2000 x g, 10 min (→ Pellet: dead cells)
⇒ 10,000 x g, 30 min (→ Pellet: cell debris)
⇒ Final 100,000 x g, 70 min → Pellet: exosomes + contaminating
proteins
⇒ Wash in PBS 100,000 x g, 70 min → Pellet: correspond to exosomes
2. Rate-zonal centrifugation
- Load exosome preparation at the gradients (0.25 - 2 M sucrose) and
centrifuge overnight (≥14 h) at 210,000 x g, 4 °C.
- With a micropipettor, collect eleven 1-mL fractions, from top to bottom.
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associated α-synuclein was more toxic to cells than the
exosome-free protein. However, since the study used a lar-
ger quantity of exosome-associated α-synuclein proteins
than actual, the effects of actual concentration of exosome-
associated α-synuclein remains unknown.
Perhaps, the most critical critique of the exosome
theory of aggregate propagation may be that this theory
relies mostly on phenomenology in that at least some se-
creted pathogenic proteins are present in the exosomes.
There is little functional evidence which demonstrates
the involvement of exosome-associated proteins in ag-
gregate propagation. Genetic modifications of exosome
formation and trafficking in cells and animals would be
one way to resolve this issue. In light of this, the study
by Hasegawa et al. [20] was alerting. In this study, when
exosome biogenesis was inhibited by silencing the ex-
pression of VPS4, a protein necessary for exosome for-
mation, secretion of α-synuclein was increased, rather
than decreased. In the same study, the authors failed to
detect α-synuclein proteins in exosome preparations
from human CSF. However, this study did not show the
effect of VPS4 silencing on intercellular a-synuclein
transmission, leaving the possibility of exosome still be-
ing important for aggregate transmission.
Alternative mechanisms
Several mechanisms other than the exosome pathway
have been proposed to explain cell-to-cell aggregate
transmission (Fig. 3). The endosome recycling pathway
is one of those mechanisms. This pathway verified its
Table 2 Summary of evidence supporting the exosomal transmission of pathogenic neurodegenerative disease proteins
Size Sedimentation Sucrose gradient Marker Reference
Prion 50-90 nm 100,000 g O Flotillin, Tsg101 [16]
Aβ 60-100 nm 100,000 g O Alix, Flotillin [35]
Not described 110,000 g X Alix, Tsg101 [13]
Tau 60-100 nm 100,000 g O Alix [37]
50-100 nm 100,000 g O Tsg101 [4]
40-100 nm 100,000 g O Alix, Flotillin [44]
α-synuclein 50-140 nm 100,000 g X Alix, Flotillin [15]
93, 99 nm 120,000 g X Alix, Flotillin, LAMP1 [3]
60-100 nm 100,000 g X Alix, Flotillin, CD63 [10]
~100 nm 100,000 g X Flotillin [40]
Fig. 3 Possible mechanisms of interneuronal protein aggregate transmission alternative to the one involving exosomes
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functional importance in the cellular amyloid precursor
protein trafficking and Aβ generation [46]. Another
unconventional secretion that might be involved in the
interneuronal aggregate transmission is exophagy, which
refers to the exocytosis mediated by fusion of autopha-
gosome/amphisome with the plasma membrane. The
release of α-synuclein monomer and aggregates was
mediated by exophagy, when the autophagosome-
lysosome fusion was impaired [2, 14]. In PC12 cell,
tubulin polymerization-promoting protein (TPPP/p25α)
co-localized with α-synuclein in autophagosomes and
inhibited the fusion of autophagosomes with lysosomes
[14]. This led to α-synuclein secretion into the media
through exophagy [14]. This study also showed that the
secretion was modulated by Rab27a, a regulator of the
late endosomal and amphisomal exocytosis [14].
Recently, another unconventional exocytosis mechanism
has been discovered and was named as misfolding-
associated protein secretion or MAPS. This mechanism
was activated when the proteasomal degradation was im-
paired [43]. Polyubiquitylated proteins were recruited to
the cytosolic surface of ER through the interaction with
USP19, an ER membrane-associated deubiquitylase [26,
43]. The misfolded proteins were then deubiquitylated and
packaged in the late endosome-like compartments before
secreted [26, 43]. The MAPS pathway is probably a part of
cellular protein quality control system, removing misfolded
proteins from cells; however, this pathway might also play
an important role in aggregate propagation.
Alternatively, direct intercellular transmission of patho-
genic proteins through the tunneling nanotubes was re-
cently proposed [1, 42]. Tunneling nanotubes are
protrusions of actin enriched structures extended from the
plasma membrane. They can be as thick as 50 to 200 nm in
diameter and be as long as up to several cell diameters [11].
In this case, the cytoplasm of neurons are directly con-
nected, which makes exocytosis of aggregates obsolete. Al-
though the evidence for transport of proteins and
organelles through tunneling nanotubes has been accumu-
lating in culture, the presence of tunneling nanotubes in
vivo, especially in the brain, has not been proven yet.
Conclusions
A growing body of literature proposes a theory that exo-
somes play important roles in the cell-to-cell transmis-
sion of pathogenic protein aggregates, thereby
contributing to the pathological and clinical progression
of neurodegenerative diseases. The exosome theory sug-
gests that pathogenic protein aggregates are encapsu-
lated into ILVs in MVBs and released from cells by
fusion of MVBs with the plasma membrane. Exosomes,
the released ILVs containing pathogenic protein
aggregates then transfer these aggregates to other cells
around.
However, the current literature possesses shortcomings
in proving the exosome theory. Notably, many of the stud-
ies analyzed crude exosomal preparations, which also con-
tain many different types of extracellular vesicles other than
exosomes and even free protein aggregates large enough to
be sedimented at the given centrifugal forces. Quantitative
analysis as to precisely how many percentages of secreted
pathogenic proteins are associated with exosomes, is miss-
ing in many of these studies. More importantly, genetic and
pharmacological intervention of exosome formation should
be employed in investigating the role of exosomes in secre-
tion and propagation of the pathogenic proteins.
In addition, given the confusion in the field as for the
definition of exosome, perhaps, one should use the term
“extracellular vesicles” rather than “exosomes”, until we
understand better the components, classification, and
biological functions of these vesicles.
Another important issue is related to the effects of
exosome-associated pathogenic proteins on the recipient
cells; how these proteins are internalized and how they in-
duce protein aggregation and neurodegeneration in the re-
cipient cells. It has been shown that free-forms of the
pathogenic aggregated proteins can be internalized into
the neuronal cells through endocytosis [7]. Therefore, the
advantages of the exosome-associated protein aggregates
over exosome-free forms in aggregate propagation and
neurodegeneration should be addressed as well as the lo-
gical basis of these benefits. In addition, the roles of other
exosomal components in aggregate propagation would be
an interesting topic for the future studies.
Although many questions remain unanswered, the
exosome theory is considered an attractive and partly
valid explanation for the intercellular propagation of
proteinopathies. Future investigation into this topic
would contribute to the disclosure of the mechanism of
protein aggregate propagation and the progression of
neurodegenerative diseases.
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